VOLUME 20, NUMBER 3 MARCH 1999

An Official Journal of The Society for Healthcare Epidemiology of America

PUBLISHED FOR THE SOCIETY BY SLACK INCORPORATED

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY™

EDITORIAL

Vancomycin-Intermediate *Staphylococcus epidermidis:* Curio or Omen?
LARRY J. STRAUSBAUGH, MD 163

ORIGINAL ARTICLES

The Emergence of Decreased Susceptibility to Vancomycin in *Staphylococcus epidermidis*
DENISE O. GARRETT, MD; ELISE JOCHIMSEN, MD; KATE MURFITT, BS; BERTHA HILL, BS; SIGRID MCALLISTER, BS; PAT NELSON, RN; RICHARD V. SPERA, MD; RICHARD K. SALL, MD; FRED C. TENOVER, PHD; JUDY JOHNSTON, MS; BARBARA ZIMMER, PHD; WILLIAM R. JARVIS, MD 167

The Prevalence of Colonization With Vancomycin-Resistant *Enterococcus* at a Veterans' Affairs Institution
JEROME I. TOKARS, MD, MPH; SACHIKO SATAKE, PHD; DAVID RIMLAND, MD; LORETTA CARSON, MS; ELAINE R. MILLER, RN, MPH; EDNA KILLUM, RN; RONDA L. SINKOWITZ-COCHRAN, BS, MPH; MATTHEW J. ARDUINO, DRPH; FRED C. TENOVER, PHD; BARBARA MARSTON, MD; WILLIAM R. JARVIS, MD 171

Management of a Sabiá Virus-Infected Patient in a US Hospital
LORI R. ARMSTRONG, PHD; LOUISE-MARIE DEMBRY, MD; PETRIE M. RAINEY, MD, PHD; MARK B. RUSSI, MD; ALI S. KHAN, MD; STEVEN H. FISCHER, MD, PHD; STEPHEN C. EDBERG, PHD; THOMAS G. KSIAZEK, DVM, PHD; PIERRE E. ROLLIN, MD; C.J. PETERS, MD 176

Surgical-Site Complications Associated With a Morphine Nerve Paste Used for Postoperative Pain Control After Laminectomy
MICHAEL H. KRAMER, MD, MPH; ALICIA J. MANGRAM, MD; MICHELE L. PEARSON, MD; WILLIAM R. JARVIS, MD 183

Epidemiology of Device-Associated Infections Related to a Long-Term Implantable Vascular Access Device
MARK J. SOTIR, MPH; CURTIS LEWIS, MD; EDWARD W. BISHER, MD; SUSAN M. RAY, MD; J. MICHAEL SOUCIE, PHD; HENRY M. BLUMBERG, MD 187

Long-Lasting Contamination of a Vitrectomy Apparatus With *Serratia marcescens*
INES KAPPSTEIN, MD; CHRISTIAN M. SCHNEIDER, MD; HAJO GRUNDMANN, MD; REGINA SCHOLZ, RN, ICP; PETER JANKNECHT, MD 192

Evaluation of the SENIC Risk Index in a Spanish University Hospital
VICTORIA VALLS, MD; MANUEL DÍEZ, MD; JAVIER ENA, MD; ALBERTO GUTIÉRREZ, MD; PEÑA GÓMEZ-HERRUZ, MD; ANTONIO MARTÍN, MD; ROSARIO GÓNZALEZ-PALACIOS, PHARMD; JAVIER GRANELL, MD 196


CONCISE COMMUNICATIONS

Evaluation of a Handwashing Intervention to Reduce Respiratory Illness Rates in Senior Day-Care Centers
ANN R. FALSEY, MD; MARY M. CRIDDLE, RN; JOHN E. KOLASSA, PHD; ROBERT M. MCCANN, MD; CHRISTINE A. BROWER, BS; WILLIAM J. HALL, MD 200

Regional Dissemination and Control of Epidemic Methicillin-Resistant *Staphylococcus aureus*
LINDSAY E. NICOLLE, MD; BRENDA DYCK, BSCN; GENEVIEVE THOMPSON, RN; SUSAN ROMAN, MD; AMIN KABANI, MD; PIERRE PLOURDE, MD; MARGARET FAST, MD; JOHN EMBIL, MD; THE MANITOBA CHAPTER OF CHICA-CANADA 202

Continued inside.

https://doi.org/10.1017/S0195941700067977 Published online by Cambridge University Press



- *Bactroban* Nasal is indicated for eradication of nasal colonization with methicillin-resistant *S. aureus* (MRSA) in adult patients and healthcare workers as part of a comprehensive infection control program to reduce the risk of infection among high-risk patients during MRSA outbreaks.[1]

Single-use tube (actual size)



- In a hospital study, *Bactroban* Nasal contributed to a dramatic reduction in MRSA infections and vancomycin costs during an outbreak.[2]
- Excellent safety profile[1]

Please see brief summary of prescribing information on adjacent page.

References: 1. Bactroban® Nasal prescribing information, 1995. **2.** Reagan DR, Dula RT, Palmer BH, et al. Control of MRSA in a VAMC with limited resources. Prog Abstr 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, U.S.A., Sept. 29-Oct. 2, 1991, p 104.

Bactroban® Nasal *mupirocin calcium*

2% ointment for intranasal use

SB SmithKline Beecham Pharmaceuticals

BN0006 ©SmithKline Beecham, 1999 Philadelphia, PA

https://doi.org/10.1017/S0195941700067977 Published online by Cambridge University Press

BACTROBAN® NASAL (mupirocin calcium ointment), 2%
Brief summary. For complete prescribing information, see package insert.

INDICATIONS AND USAGE
Bactroban Nasal is indicated for eradication of nasal colonization with methicillin-resistant *Staphylococcus aureus* in adult patients and health care workers as part of a comprehensive infection control program to reduce the risk of infection among patients at high risk of methicillin-resistant *S. aureus* infection during institutional outbreaks of infections with this pathogen.

NOTE:
(1) There are insufficient data at this time to establish that this product is safe and effective as part of an intervention program to prevent autoinfection of high-risk patients from their own nasal colonization with *S. aureus*.
(2) There are insufficient data at this time to recommend use of *Bactroban* Nasal for general prophylaxis of any infection in any patient population.
(3) Greater than 90% of subjects/patients in clinical trials had eradication of nasal colonization 2 to 4 days after therapy was completed. Approximately 30% recolonization was reported in one domestic study within 4 weeks after completion of therapy. These eradication rates were clinically and statistically superior to those reported in subjects/patients in the vehicle-treated arms of the adequate and well-controlled studies. Those treated with vehicle had eradication rates of 5% to 30% at 2 to 4 days post-therapy with 85% to 100% recolonization within 4 weeks.

CONTRAINDICATIONS
Bactroban Nasal is contraindicated in patients with known hypersensitivity to any of the constituents of the product.

WARNINGS
AVOID CONTACT WITH THE EYES. Application of *Bactroban* Nasal to the eye under testing conditions has caused severe symptoms such as burning and tearing. These symptoms resolved within days to weeks after discontinuation of the ointment.

In the event of a sensitization or severe local irritation from *Bactroban* Nasal, usage should be discontinued.

PRECAUTIONS
General: As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible microorganisms, including fungi. (See DOSAGE AND ADMINISTRATION in complete prescribing information.)

Information for Patients: Patients should: apply approximately one-half of the ointment from the single-use tube directly into one nostril and the other half into the other nostril; avoid contact of the medication with the eyes; discard the tube after using; press the sides of the nose together and gently massage after application to spread the ointment throughout the inside of the nostrils; and discontinue using *Bactroban* Nasal and call a health care practitioner if sensitization or severe local irritation occurs.

Drug Interactions: The effect of the concurrent application of intranasal mupirocin calcium and other intranasal products has not been studied. Do not apply mupirocin calcium ointment, 2% concurrently with any other intranasal products.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals to evaluate carcinogenic potential of mupirocin calcium have not been conducted. Results of the following studies performed with mupirocin calcium or mupirocin sodium *in vitro* and *in vivo* did not indicate a potential for mutagenicity: rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, *Salmonella* reversion test (Ames), *Escherichia coli* mutation assay, metaphase analysis of human lymphocytes, mouse lymphoma assay, and bone marrow micronuclei assay in mice. Reproduction studies were performed in rats with mupirocin administered subcutaneously at doses up to **40** times the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m^2 basis and revealed no evidence of impaired fertility from mupirocin sodium.

Pregnancy: Teratogenic Effects. Pregnancy Category B. Reproduction studies have been performed in rats and rabbits with mupirocin administered subcutaneously at doses up to 65 and 130 times, respectively, the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m^2 basis and revealed no evidence of harm to the fetus due to mupirocin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when *Bactroban* Nasal is administered to a nursing woman.

Pediatric Use: Safety in children under the age of 12 years has not been established. (See CLINICAL PHARMACOLOGY in complete prescribing information.)

ADVERSE REACTIONS
Clinical Trials: In clinical trials, 210 domestic and 2,130 foreign adult subjects/patients received *Bactroban* Nasal ointment. Less than 1% of domestic or foreign subjects and patients in clinical trials were withdrawn due to adverse events. In domestic clinical trials, 17% (36/210) of adults treated with *Bactroban* Nasal ointment reported adverse events thought to be at least possibly drug-related. The incidence of adverse events thought to be at least possibly drug-related that were reported in at least 1% of adults enrolled in domestic clinical trials were as follows: headache, 9%; rhinitis, 6%; respiratory disorder, including upper respiratory tract congestion, 5%; pharyngitis, 4%; taste perversion, 3%; burning/stinging, 2%; cough, 2%; and pruritus, 1%.

The following events thought possibly drug-related were reported in less than 1% of adults enrolled in domestic clinical trials: blepharitis, diarrhea, dry mouth, ear pain, epistaxis, nausea and rash. All adequate and well-controlled clinical trials have been performed using *Bactroban* Nasal ointment, 2% in one arm and the vehicle ointment in the other arm of the study.

OVERDOSAGE
Following single or repeated intranasal applications of *Bactroban* Nasal to adults, no evidence for systemic absorption of mupirocin was obtained.

Manufactured by **DPT Laboratories, Inc.**, San Antonio, TX 78215

Distributed by **SmithKline Beecham Pharmaceuticals**, Philadelphia, PA 19101

BN:L1

Good medicine for your career

At St. Rita's Medical Center, a 400+ bed regional referral center located in West Central Ohio, human dignity, compassionate care and advanced medical technologies combine to provide the highest quality care. Discover professional rewards and personal satisfaction in a team-oriented environment.


Infection Control Coordinator
Full Time

We have an immediate full time opportunity for an Infection Control Coordinator to manage the hospital-wide Infection Control program. Responsibilities will include originating and reviewing policies and procedures; functioning as a resource for physicians, staff, and patients; assuring compliance with regulatory guidelines; and providing orientation and continuing education for staff members.

Successful candidates must have a minimum of a B.S. degree with Medical Technology registration or an R.N. license with demonstrated problem solving, communication and data analysis skills. Knowledge of Epidemiologic Principles, sterilization and disinfection procedures also required. Must have familiarity with patient care equipment and procedures, as well as knowledge of, and experience with, state, federal and JCAHO regulations. CIC certification in Infection Control, or willing to obtain, will be required.

We offer salary commensurate with experience and flexible benefits. Qualified candidates may apply in person, or mail/fax/email resume to: **Employment Manager, St. Rita's Medical Center, 730 W. Market St., Lima, OH 45801, PH: (419) 226-9548 or 1-800-232-7762 ext. 9548, FAX: (419) 226-9870, Email: javantilburgh@health-partners.org**

St. Rita's is an equal opportunity employer.



MEDICAL MATRIX Ranked, Peer-Reviewed, Annotated, Updated, Clinical Medicine Resources

- MEDLINE
- JOURNALS
- CME
- NEWS
- RX ASSIST
- TEXTBOOKS
- STAT SEARCH NEW!
- PATIENT EDUCATION
- MARKETPLACE

THE LARGEST PEER-REVIEWED, ANNOTATED AND RATED INTERNET MEDICAL DIRECTORY

VISIT MEDICAL MATRIX FOR *FREE* ACCESS TO THE BEST MEDICAL SITES ON THE WEB

http://www.medmatrix.org
(Registration Required)

Reviewed and updated continuously by an Editorial Board comprised of Physicians and Medical Informatics Specialists

For advertising opportunities contact M. Long

https://doi.org/10.1017/S0195941700067977 Published online by Cambridge University Press

SHEA

The Society for Healthcare Epidemiology of America

1999 SHEA/CDC Training Course in Hospital Epidemiology

Program

The program will be held May 1-4, 1999 at the Wyndham Franklin Plaza Hotel, Philadelphia, Pennsylvania. Timothy W. Lane, M.D., Gina Pugliese, R.N., and Julie Gerberding, M.D. will chair the program.

Purpose

This program, developed by the Society for Healthcare Epidemiology of America (SHEA), and the Centers for Disease Control and Prevention (CDC), is intended for infectious disease fellows and new hospital epidemiologists. It emphasizes hands-on exercises in which participants work in small groups to detect, investigate, and control epidemiological problems encountered in the hospital setting. These work sessions are supplemented with lectures and seminars covering fundamental aspects of hospital epidemiology and surveillance, epidemic investigation, transmission and control of nosocomial infections, disinfection and sterilization, employee health, isolation systems, regulatory compliance, and quality improvement.

Who Should Attend

You should attend if you are a hospital epidemiologist or an infection control practitioner or if you are looking for a course that will provide you the most current information concerning infection control practices and epidemiological methods in health care. This fundamental program will provide you with the opportunities to find solutions to real situations that will occur in the hospital setting. Intensive problem solving sessions are supplemented with lectures and seminars presented by leading authorities.

Scholarships

Scholarships in the amount of $1,000 will be awarded to infectious disease fellows for the program to defray the special course fee for fellows of $350 and expenses incurred in attending the training program.

Interested fellows must submit a letter of no more than one page describing why they would like to have additional training in hospital epidemiology. A letter from the fellow's program director outlining the applicant's qualifications and suitability for the course also is required. The deadline for receipt of scholarship applications for the course is March 26, 1998.

The SHEA Educational Activities Committee will select the scholarship recipients based on review of these letters. Winners will be notified in September.

Nominations

Please send scholarship applications to:

Timothy W. Lane, M.D.
c/o The Society for Healthcare Epidemiology of America
19 Mantua Road
Mt. Royal, NJ 08061

Fees

Individual Registrants	$495
Fellows in Infectious Disease	$350

Credits

The Society for Healthcare Epidemiology of America (SHEA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

SHEA designates this continuing education activity for up to 23 hours in Category 1 of the Physician's Recognition Award of the American Medical Association.

The SHEA/CDC Training Course is AACN (American Association of Critical Care Nurses) approved for 28.5 hours.

General Course Information

Information regarding the schedule, hotel and travel accommodations, discount airfare, and course fees are available from SHEA (609) 423-7222 x350. Note that application for a scholarship does not constitute enrollment in the program. This must be done separately.

Scholarship Awards provided in part by an educational grant from Pfizer Pharmaceuticals.

Pfizer Labs • NHO • Pratt • Roerig • Specialty
U.S. Pharmaceuticals Group

https://doi.org/10.1017/S0195941700067977 Published online by Cambridge University Press

Vol. 20 No. 3 March 1999

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY®

CONTENTS

Continued from cover

Nosocomial Infections With Ceftazidime-Resistant *Pseudomonas aeruginosa*: Risk Factors and Outcome
SAI-CHEONG LEE, MD; CHANG-PHONE FUNG, MD; PETER YUK-FONG LIU, MD, MSc; TZU-CHIEN WANG, PHD; LAI-CHU SEE, PHD; NING LEE, MD; SHU-CHU CHEN, RN; WEN-BIN SHIEH, MD 205

THE INTERNATIONAL PERSPECTIVE

The Effect of Frequency of Chart Review on the Sensitivity of Nosocomial Infection Surveillance in General Surgery
MIGUEL DELGADO-RODRÍGUEZ, MD, PHD; ANTONIO GÓMEZ-ORTEGA, MD; ANTONIO SIERRA, MD, PHD; TRINIDAD DIERSSEN, MD; JAVIER LLORCA, MD, PHD; MARÍA SILLERO-ARENAS, MD, PHD 208

LETTERS TO THE EDITOR

Hepatitis B and Hemodialysis: The Impact of Universal Precautions in Preventing the Transmission of Bloodborne Viruses (with reply)
ROB LYERLA, PHD; SCOTT KELLERMAN, MD, MPH; MIRIAM J. ALTER, PHD; ALOYS C.M. KROES, MD, PHD; ERIC F.H. VAN BOMMEL, MD, PHD; JAN A.J.W. KLUYTMANS, MD, PHD; WILLEM WEIMAR, MD, PHD 156

Risk of Tuberculosis Transmission in an Adult Day-Care Center
JUDITH E. WOLF, MD; JAMES L. DEAN, MD 157

Level of Suspicion of Pulmonary Tuberculosis Over a 4-Year Period in a Teaching Hospital
ANNIE-CLAUDE LABBÉ, MD; KARL WEISS, MD, FRCPC; MICHEL LAVERDIERE, MD, FRCPC; LOUISE POIRER, MD, FRCPC 158

Tuberculosis Contact Tracing Among Healthcare Workers: Source-Case Selection, Method of Tracing, and Outcome of Follow-Up
JOSEPH BARAN, JR, MD; HITPREET SANGHERA, MD; RIAD KHATIB, MD 160

MEDICAL NEWS
GINA PUGLIESE, RN, MS; MARTIN S. FAVERO, PHD 213

SHEA NEWS
ANDREAS VOSS, MD, PHD 216

To view abstracts of these articles, visit us on the Internet at http://www.slackinc.com/general/iche

THE PUBLICATION OF ADVERTISING IN THE JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA OR SLACK INCORPORATED OF THE ADVERTISED PRODUCT OR SERVICE OR OF CLAIMS MADE BY THE ADVERTISER. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT THE POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE SOCIETY.

PUBLISHER: Infection Control and Hospital Epidemiology (ISSN-0899-823X, Canadian GST#129780466) is published exclusively by SLACK Incorporated 12 times a year. Address: 6900 Grove Rd., Thorofare, NJ 08086. Telephone: (609) 848-1000.

SHEA: 19 Mantua Rd., Mt. Royal, NJ 08061; telephone, 609-423-0087; fax, 609-423-3420; e-mail address, sheahq@talley.com.

COPYRIGHT 1999 The Society for Healthcare Epidemiology of America, Inc., and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. Printed in the USA.

SUBSCRIPTIONS: Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year-$105.00; Two years-$143.00; Three years-$176.00; Institutional: One year-$128.00; Two years-$178.00; Three years-$228.00. Fellows: $52.50 per year with proof of training status. Canada: $20.00 additional each year plus 7% for Canadian Goods & Services tax; Overseas surface, $145.00 each year; Overseas air mail, $190.00. Single copies of current issues may be obtained for $15.00, United States and possessions; $20.00 all other countries.

INSTRUCTIONS TO AUTHORS: Authors may submit manuscripts prepared in accordance with the 1997 revision of the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals." The Uniform Requirements has been published in several journals, including *Infect Control Hosp Epidemiol* 1997;18:457-464 and *Ann Intern Med* 1997;126:36-47. A digital version is available on our web site (http://www.slackinc.com/general/iche/ichehome.htm). Submit to ICHE Editorial Offices, Vanderbilt University School of Medicine, A-1131 Medical Center North, Nashville, TN 37232-2637, USA. All submissions must be accompanied by copyright form(s) signed by all authors (see January issue or our web site).

REPRINTS: All requests to reprint or use material published herein should be addressed to Karen Lambertson, SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086. For reprint orders and prices, contact Karen Lambertson at (609) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of $1.00 per copy, plus $.15 per page is paid directly to Copyright Clearance Center, 27 Congress St., Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

CHANGE OF ADDRESS: Notice should be sent to the publisher 6 weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Periodicals postage paid at Thorofare, New Jersey 08086-9447 and at additional mailing offices. POSTMASTER: Send address changes to SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents-Clinical Practice, Hospital Literature Index, Cumulative Index to Nursing & Allied Health Literature, Nursing Abstracts, Laboratory Performance Information Exchange System, and RNdex Top 100.

https://doi.org/10.1017/S0195941700067977 Published online by Cambridge University Press

NOW AVAILABLE ON CD-ROM:

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOG

1987-1997

Simplifying your reference library is easy, with 10 years of INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY now available on CD-ROM. As the official journal of the Society of Healthcare Epidemiology of America (SHEA), this ready reference will allow the user to quickly and easily access articles and studies from 1987-1997 that can help put current issues of epidemiology and infection control in perspective.

Easy and Convenient CD-ROM Technology

The INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM will take full advantage of the latest CD-ROM technology, including:

- fully searchable text
- annual indexes organized by category, page number, subject and author
- convenient annual updates
- PC and Mac compatibility

The INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM packs an enormous amount of information in a small space at a comparably small price! Adding 10 years of this informative journal to your library is a bargain, at special prices starting as low as $147.

Money-Back Guarantee

The Society of Healthcare Epidemiology of America is always looking for innovative ways to keep you informed of important developments in infection control and hospital epidemiology. We are sure you will refer to the information in the INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM often. If you aren't satisfied, we offer a 30-day money-back guarantee.*

To order, call us at **800-257-8290** or **609-848-1000** (in NJ); or write to
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
6900 Grove Rd., Thorofare, NJ 08086

Appx. pub. date: 10/98



❒ **Yes!** Please send me the INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM. Enclosed is a check or money order for the amount/quantity checked below.

❒ SHEA Member:	$147.00 ea.	Qty: _____
❒ Individual Non-Member:	$197.00 ea.	Qty: _____
❒ Institution:	$247.00 ea.	Qty: _____

Or bill my ❒ Visa ❒ Mastercard ❒ Amex

Acct. No. _____ Exp. date: ____/____/____

Signature: _____

Send CD-ROM to:

Name _____

Address _____

City _____ State _____ Zip _____

Phone _____ FAX _____

Send order and make check payable to:
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY • 6900 Grove Rd. • Thorofare, NJ 08086
Or FAX your order to: (609) 853-5991
For fastest service, call today: 1-800-257-8290 or 609-848-1000 (in NJ)

*If not completely satsfied with the INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM, just return it within 30 days and your money will be refunded.

988191 Exp: 4/99

https://doi.org/10.1017/S0195941700067977 Published online by Cambridge University Press

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY™

EDITORIAL OFFICES
Vanderbilt University School of Medicine
A-1131 Medical Center North
Nashville, TN 37232-2637
(615) 343-1095; (615) 343-1882 (FAX)
Email: iche@mcmail.vanderbilt.edu

EDITOR
Michael D. Decker, MD, MPH
MANAGING EDITOR
Susan Cantrell
STATISTICAL EDITOR
Beverly G. Mellen, PhD
SENIOR ASSOCIATE EDITORS
C. Glen Mayhall, MD
Gina Pugliese, RN, MS
William Schaffner, MD
ASSOCIATE EDITORS
Donald A. Goldmann, MD
Didier Pittet, MD, MS
Andreas Widmer, MD, MS
SECTION EDITORS
Beyond Infection Control: The New Hospital Epidemiology
Bryan P. Simmons, MD
Stephen B. Kritchevsky, PhD
Memphis, Tennessee
Wing Hong Seto, MD
Hong Kong
Disinfection and Sterilization
William A. Rutala, PhD, MPH
Chapel Hill, North Carolina
Emerging Infectious Diseases
Larry J. Strausbaugh, MD
Portland, Oregon
Robert W. Pinner, MD
Atlanta, Georgia
From the Laboratory
Marcus Zervos, MD
Royal Oak, Michigan
Fred C. Tenover, PhD
Atlanta, Georgia
Information Management
John A. Sellick, DO
Buffalo, New York
The International Perspective
Mary D. Nettleman, MD, MS
Richmond, Virginia
Issues in Surgery
James T. Lee, MD, PhD
St. Paul, Minnesota
Medical News
Gina Pugliese, RN, MS
Chicago, Illinois
Martin S. Favero, PhD
Irvine, California
Practical Healthcare Epidemiology
Loreen A. Herwaldt, MD
Iowa City, Iowa
SHEA News
Andreas Voss, MD, PhD
Nijmegen, The Netherlands
Statistics for Hospital Epidemiology
David Birnbaum, PhD, MPH
Sidney, British Columbia, Canada
Topics in Long-Term Care
Philip W. Smith, MD
Omaha, Nebraska
Topics in Occupational Medicine
David Weber, MD, MPH
Chapel Hill, North Carolina

EDITORIAL ADVISORY BOARD

Jacques F. Acar, MD	Paris, France
J. Wesley Alexander, MD	Cincinnati, Ohio
Paul Arnow, MD	Chicago, Illinois
Graham A.J. Ayliffe, MD	Birmingham, United Kingdom
Neil L. Barg, MD	Yakima, Washington
Elizabeth Ann Bolyard, RN, MPH, CIC	Atlanta, Georgia
John M. Boyce, MD	Providence, Rhode Island
Professor Dr. Ilja Braveny	Munich, Federal Republic of Germany
Charles Bryan, MD	Columbia, South Carolina
Christian Brun-Buisson, MD	Creteil, France
Donald E. Craven, MD	Boston, Massachusetts
Sue Crow, MSN, RN, CIC	Shreveport, Louisiana
Franz Daschner, MD	Freiburg, Federal Republic of Germany
Leigh G. Donowitz, MD	Charlottesville, Virginia
Charles E. Edmiston, Jr., PhD	Milwaukee, Wisconsin
Theodore C. Eickhoff, MD	Denver, Colorado
Bruce Farber, MD	Manhasset, New York
Victoria J. Fraser, MD	St. Louis, Missouri
Peter C. Fuchs, MD, PhD	Black Butte, Oregon
Richard A. Garibaldi, MD	Farmington, Connecticut
Velvl Greene, PhD, MPH	Beer Sheva, Israel
Robert Gaynes, MD	Atlanta, Georgia
David W. Gregory, MD	Nashville, Tennessee
David K. Henderson, MD	Bethesda, Maryland
Peter N.R. Heseltine, MD	Los Angeles, California
Karen Hoffmann, RN, CIC, MS	Chapel Hill, North Carolina
Marguerite McMillan Jackson, RN, PhD	San Diego, California
Janine Jagger, MPH, PhD	Charlottesville, Virginia
William R. Jarvis, MD	Atlanta, Georgia
Douglas S. Kernodle, MD	Nashville, Tennessee
Robert H. Latham, MD	Nashville, Tennessee
Lewis B. Lefkowitz, MD	Nashville, Tennessee
Hsieh-Shong Leu, MD, MSc	Taipei, Taiwan
Jack Levy, MD	Brussels, Belgium
Victor Lorian, MD	Bronx, New York
Dennis G. Maki, MD	Madison, Wisconsin
Professor Dr. Walter Marget	Munich, Federal Republic of Germany
William J. Martone, MD	Bethesda, Maryland
Allison McGeer, MD	Toronto, Ontario, Canada
John E. McGowan, Jr., MD	Atlanta, Georgia
Jonathan L. Meakins, MD, DSc	Montreal, Quebec, Canada
Raf Mertens, MD	Brussels, Belgium
Robert R. Muder, MD	Pittsburgh, Pennsylvania
Joseph M. Mylotte, MD, CIC	Buffalo, New York
Lindsay Nicolle, MD	Winnepeg, Manitoba, Canada
Juhani Ojajärvi, MD	Helsinki, Finland
Michael T. Osterholm, PhD, MPH	Minneapolis, Minnesota
Jan Evans Patterson, MD	San Antonio, Texas
Sindy M. Paul, MD	Trenton, New Jersey
Michael A. Pfaller, MD	Iowa City, Iowa
Samuel Ponce de Leon, MD, MSc	Mexico City, Mexico
Isaam Raad, MD	Houston, Texas
Manfred L. Rotter, MD, DipBact	Vienna, Austria
Theodore Sacks, MD	Jerusalem, Israel
William E. Scheckler, MD	Madison, Wisconsin
Kent Sepkowitz, MD	New York City, New York
Denis Spelman, MD	Prahran Victoria, Australia
Michael L. Tapper, MD	New York, New York
Clyde Thornsberry, PhD	Brentwood, Tennessee
Professor Leonid P. Titov	Minsk, Republic of Belarus
Timothy R. Townsend, MD	Millwood, Virginia
Antoni Trilla, MD, PhD	Barcelona, Spain
Professor Wang Shu-Qun	Beijing, People's Republic of China
J. John Weems, Jr., MD	Greenville, South Carolina
Robert A. Weinstein, MD	Chicago, Illinois
Professor Dr. W. Weuffen	Greifswald, Federal Republic of Germany
Sergio B. Wey, MD	São Paulo, Brazil
Rebecca Wurtz, MD	Evanston, Illinois

SLACK Incorporated
6900 Grove Road
Thorofare, New Jersey 08086
(609) 848-1000

Vice President/Group Publisher
Richard N. Roash
Publisher
John C. Carter
Editorial Director
Jennifer Kilpatrick
Production Editor
Shirley P. Strunk, ELS
Assistant Editor
Eileen C. Anderer


Circulation Manager
Lester J. Robeson, CCCP
Production Director
Christine Malin
Production Coordinator
Joanne Patterson
Publishing Director/ Advertising
Wayne McCourt
Pharmaceutical Group Sales Director
Michael LoPresti

Advertising Sales Representative
Jennine Kane
Classified/Recruitment Sales Manager
Kathy Huntley
Classified/Recruitment Sales Representative
Kelly Wark

https://doi.org/10.1017/S0195941700067977 Published online by Cambridge University Press

ALL THE ANSWERS UNDER ONE COVER

Just Released!



A Practical Handbook for Hospital Epidemiologists

Edited by Loreen A. Herwaldt, MD
and co-edited by Michael D. Decker, MD, MPH

Soft Cover, 448 pp, ISBN 1-55642-302-0, Order# 13020, $60.00

A Practical Handbook for Hospital Epidemiologists is the most complete source for practical advice on hospital epidemiology. It is intended to be a pragmatic guide that will assist both beginning and experienced epidemiologists in establishing and operating a successful hospital epidemiology program.

This handbook will supplement the various scientific references already available for hospital epidemiologists. It will provide practical information and advice regarding many aspects of operating a hospital epidemiology program and will help hospital epidemiologists improve their practices.

The Society for Healthcare Epidemiology of America (SHEA) has recruited the most recognized leaders in the field to share their expertise. They will share successful strategies for handling specific situations. The authors cover many topics that every newcomer should know but are usually learned through experience. These topics include:

- **Overarching goals and ethical principles you should adopt to guide your practice**
- **What you can do to educate yourself**
- **How to negotiate with the administration and communicate with colleagues**
- **How to develop policies and procedures**
- **How to develop a surveillance system**

Contents

Getting Started
Chapter 1: An Introduction to Practical Hospital Epidemiology
Chapter 2: The Hospital Epidemiologist: Practical Ideas
Chapter 3: Educational Needs and Opportunities for the Hospital Epidemiologist
Chapter 4: Negotiating with the Administration—or How to Get Paid for Doing Hospital Epidemiology
Chapter 5: The Infection Control Committee
Chapter 6: Developing Policies and Guidelines
Chapter 7: Intramural and Extramural Communication
Chapter 8: Ethical Aspects of Infection Control
Surveillance and Analysis
Chapter 9: Basics of Surveillance—An Overview
Chapter 10: Hospital-Acquired Pneumonia: Perspectives for the Healthcare Epidemiologist
Chapter 11: Basics of Surgical Site Infection Surveillance
Chapter 12: Surveillance for Infections Associated with Vascular Catheters
Chapter 13: Designing Surveillance for Noninfectious Outcomes of Medical Care
Chapter 14: Outbreak Investigations
Chapter 15: Exposure Workups
Chapter 16: Isolation
Chapter 17: Basics of Stratifying for Severity of Illness
Chapter 18: Quantitative Epidemiology
Support Functions
Chapter 19: Microcomputers in Hospital Epidemiology
Chapter 20: The Computer-Based Patient Record: The Role of the Hospital Epidemiologist
Chapter 21: Basic Microbiologic Support for Hospital Epidemiology
Chapter 22: Epidemiologic Typing Systems
Special Topics
Chapter 23: Epidemiologic Approaches to Quality Assessment
Chapter 24: Disinfection and Sterilization of Patient Care Items
Chapter 25: Controlling Use of Antimicrobial Agents
Chapter 26: Employee Health and Infection Control
Chapter 27: Tuberculosis Control in Healthcare
Chapter 28: Infection Control Issues in Construction and Renovation
Chapter 29: Hospital Epidemiology in Smaller Hospitals
Chapter 30: Infection Control in Public Hospitals
Chapter 31: Infection Control in Long-Term Care Facilities
Chapter 32: Infection Control in the Outpatient Setting
Chapter 33: OSHA Inspections
Chapter 34: Preparing for and Surviving a JCAHO Inspection
Chapter 35: Product Evaluation

Order Coupon

__Yes, Send me ___copies of *A Practical Handbook for Hospital Epidemiologists* (Order# 13020) at the Special Introductory Price of **$60.00** each. (Shipping may apply.) Foreign orders add $25.00 USD for direct air-freight shipping to your location.

Subtotal $_____
Handling charge $ 4.50
NJ residents add 6% sales tax $_____
Total $_____

Please print
Name _____
Address _____
City _____
State/Country _____
Zip _____
Phone _____ Fax _____

__Check enclosed (payable to SLACK Inc., in US dollars drawn on a US bank)
__Charge My ___Visa ___Mastercard ___American Express
Account No. _____ Exp. _____
Signature _____

SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086-9447, USA

To order call (in the US) 800-257-8290 or 609-848-1000
Fax orders to 609-853-5991
Order on-line: orders@slackinc.com
http://www.slackinc.com
All Prices Are Subject To Change CODE 4A345

https://doi.org/10.1017/S0195941700067977 Published online by Cambridge University Press

SHEA

CDC Guidelines
for Surveillance Prevention & Control of Nosocomial Infections

All In One Single Volume for only $99.00*
Plus Shipping & Handling

Urinary Tract Infections • Surgical Wound Infections
Handwashing and Environmental Control
Hospital Personnel • HIV and HBV Exposure-Prone Procedures • Pneumonia Tuberculosis
Vancomycin Resistance • IV Device-Related Infections • Isolation Precautions
HIV Post-Exposure Chemoprophylaxis
HCV Post-Exposure Prophylaxis
and Index of SHEA Position Papers

Foreword by Julia S. Garner, RN, MN


To Order Call 1-800-552-0076

International Orders 414-634-0806
E-mail ETNAComm@aol.com

*SHEA Journal Subscribers mention this ad for 10% discount.
Orders outside the U.S.A., Canada, & Mexico are $175.00 each. SJ198

Consumer Information Catalog

www.pueblo.gsa.gov



9 out of 10 mice prefer the Consumer Information Catalog online. Just point and click your way to **www.pueblo.gsa.gov** and you'll find more than 250 free publications ready to read or download.

U.S. General Services Administration

Finding the source of an infection in hours, not days.

A university teaching hospital noted increased infections caused by an antibiotic-resistant strain of *Pseudomonas aeruginosa.* Physicians noted resistance to imipenem, but were perplexed because, of the patients who cultured positive for the strain, only 15% had received imipenem.

The RiboPrinter® Microbial Characterization System took only eight hours to genetically fingerprint isolates and revealed that 85% of the infected patients shared the identical strain of *P. aeruginosa.* When hospital epidemiologists found that 85% of these patients had been intubated in the Shock Trauma Center (STC), they knew the increased incidence was due to nosocomial transmission.

Environmental culturing turned up *P. aeruginosa* in a pipe leading to the faucet in the STC and the RIboPrinter® system revealed that it was the identical strain to the one found in the patients. A simple chlorine rinse of the pipe eradicated the organism and the infections did not return.

Only the RiboPrinter® system's precise, fast, strain-level typing could have enabled hospital staff to pinpoint their cleanup efforts at the source of the nosocomial infection, saving the hospital time and money and minimizing the suffering of patients.

What can the RiboPrinter® system do for you?
Find out. Call 1.800.863.6842.
In Europe, call +44 (0) 1926.404008.

Qualicon™
A DuPont Subsidiary



www.qualicon.com

https://doi.org/10.1017/S0195941700067977 Published online by Cambridge University Press